Tergus is excited to announce that we are joining forces with MedPharm Ltd to establish the best-in-class end-to-end topical and transepithelial CDMO. Michael Kane has been appointed CEO of the merged company, which will operate under the MedPharm name. Michael previously served as the CEO of Tergus. The combined business will continue offering full commercial production capabilities, including high-potency and hormone-based drugs, and comprehensive serialization services. This merger adds enhanced automation, innovation, and expertise to our in vitro testing services, in addition to cutting-edge research models for drug development. Furthermore, with an expanded presence in the U.S. and facilities and MHRA/EMA experts in the U.K., our combined organization will be able to serve our clients with a global regulatory focus. The merger uniquely positions MedPharm as the premier CDMO focused on topical and transepithelial drug products. Click here to learn more: https://hubs.la/Q02FB52G0
MedPharm Ltd (formerly Tergus Pharma)
Pharmaceutical Manufacturing
Durham, NC 17,237 followers
About us
Getting a promising new topical or transepithelial product from lab to patient is challenging. Making it all the way through the development pipeline will be time-consuming, risky, and unpredictable. That’s why it makes sense to think ahead and partner with the experts who can give pharma companies like yours more opportunities for success, every step of the way. As a global CDMO focused only on topical and transepithelial delivery methods, MedPharm has the proven ability to understand and anticipate the needs of our partners—even in the face of market changes, regulatory environments, or scientific advancements. Whether through our robust and innovative research methods, clinical trial material manufacturing, or full-scale commercial production, you can entrust every aspect of your drug pipeline to MedPharm—the global gold standard in topical and transepithelial CDMO services.
- Website
-
https://www.medpharm.com
External link for MedPharm Ltd (formerly Tergus Pharma)
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Durham, NC
- Type
- Privately Held
- Specialties
- Topical Product Development, Analytical Testing Laboratory, In Vitro Release Testing, Contract Research Organization, Product Testing Laboratory, Skin Permeation, Pharmaceutical Testing Services, Dermatology Product Development, GMP manufacturing, pharmaceutical manufacturing, and topical pharmaceutical manufacturing
Locations
-
Primary
Get directions
4018 Stirrup Creek Dr
Durham, NC 27703, US
Employees at MedPharm Ltd (formerly Tergus Pharma)
Updates
-
Here in Philly with my colleague Tim Miley, ready to talk about Tergus' CDMO services!
We’re open for business at CPHI North America in Philadelphia! Come by booth 642 to talk about how Tergus can support your topical drug development and commercial production. #TeamTergus #TergusCDMO #CPHINorthAmerica
-
-
We’re open for business at CPHI North America in Philadelphia! Come by booth 642 to talk about how Tergus can support your topical drug development and commercial production. #TeamTergus #TergusCDMO #CPHINorthAmerica
-
-
CPhI North America 2024 is here! Don’t miss a great opportunity to discuss your topical product with the topical experts at Booth #642! #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalManufacturing
-
-
Did you know that Tergus has a purpose-built, cGMP, full-commercial production facility for topical products, including batch sizes from 30L to 1500L, separate dedicated HPAPI and hormone suites, and packaging capabilities for full turnkey CMO services? Let’s talk about it at CPhI North America next week, Booth #642. #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction
-
-
CPhI North America is a week away, so let’s schedule a meeting at our Booth #642 to discover how Tergus can put our unrivaled expertise in early- & late-stage R&D and full-scale commercial production to work for your topical product program. #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalManufacturing
-
-
Did you know that April is Rosacea Awareness Month? Rosacea is a common skin condition effecting 415 million people around the world. Rosacea causes flushing or long-term redness on the face. Symptoms can come and go, with flare-ups lasting for weeks or months. While there is no cure, symptoms can be controlled with medical therapy. As a leader in the development and manufacture of topical treatments, Tergus is committed to helping our clients find new products to treat this disease. https://hubs.la/Q02qYPyY0 #Rosacea #RosaceaAwarenessMonth #topicalformulations #topicalmanufacturing
-
-
DCAT Week 2024 is here! Don’t miss a great opportunity to discuss your topical product with the topical experts! https://hubs.la/Q02jpfVV0 #DCATWeek2024 #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction
-
-
We’re rolling out the red carpet for our meeting guests at the Lotte New York Palace during DCAT Week next week. If you have a topical drug product in your portfolio, we should talk. https://hubs.la/Q02jpfWF0 #DCATWeek2024 #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction
-
-
Ready to kick off the AID Dermatology Innovation Forum today in San Diego as a proud AID sponsor. #AIDDermatologyInnovationForum2024 #TopicalCDMO #TopicalDrugDevelopment #TopicalFormulation #TopicalProduction
-